Once-daily formulation of dexmethylphenidate achieved primary endpoint (p 0.001) with consistent symptom relief up to 12 hours post-dose KANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results